Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
IPO Year: 2020
Exchange: NYSE
Website: nuvationbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2025 | Buy | Truist | |
| 11/19/2025 | $12.00 | Buy | B. Riley Securities |
| 9/30/2025 | $10.00 | Buy | Jefferies |
| 4/23/2025 | $6.00 | Mkt Outperform | Citizens JMP |
| 3/27/2024 | $1.40 → $10.00 | Hold → Buy | Jefferies |
| 3/26/2024 | $5.00 | Neutral → Buy | BTIG Research |
| 1/6/2023 | $5.00 → $2.00 | Buy → Hold | Jefferies |
| 8/2/2022 | $8.00 → $2.50 | Outperform → Market Perform | BMO Capital Markets |
| 8/2/2022 | Buy → Neutral | BTIG Research | |
| 5/4/2022 | $14.00 | Buy | H.C. Wainwright |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Truist initiated coverage of Nuvation Bio with a rating of Buy
B. Riley Securities initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $12.00
Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00
Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00
Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously
BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00
Jefferies downgraded Nuvation Bio from Buy to Hold and set a new price target of $2.00 from $5.00 previously
BMO Capital Markets downgraded Nuvation Bio from Outperform to Market Perform and set a new price target of $2.50 from $8.00 previously
BTIG Research downgraded Nuvation Bio from Buy to Neutral
H.C. Wainwright initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $14.00
Fastest customizable press release news feed in the world
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-upNew Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced updated positive long-term follow-up data from the Phase 2 (J201) study of safusidenib in patients with chemotherapy- and ra
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes"). The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant to the Greenshoe Exercise. On July 1, 2
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approvalNEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million. The sale of the Notes to the underwriters is expected to close on June 30, 2026, subject to customary closing conditions. Nuvation Bio also granted the underwriters of the Notes a right to purchase, exercisable within 30 days
NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if
NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:55 a.m. ET in New York, NY. A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bi
88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatmentCognitive function scores improved or remained stable throughout the course of treatment with IBTROZIIBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breathNEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung can
Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United StatesMove by Nuvation Bio further ensures critical drug supply for patients and providersNEW YORK, May 13, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The transition was submitted as a su
Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II TKI-pretreated mDOR of nearly 20 months FDA has assigned a target action date of January 4, 2027NEW YORK, May 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI® (taletrectinib) in both TKI-naïve and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCL
NEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences: Bank of America Securities 2026 Healthcare Conference – fireside chat on Wednesday, May 13, 2026, at 8:00 a.m. PT in Las Vegas, NVH.C. Wainwright 4th Annual BioC
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
424B5 - Nuvation Bio Inc. (0001811063) (Filer)
305B2 - Nuvation Bio Inc. (0001811063) (Filer)
FWP - Nuvation Bio Inc. (0001811063) (Subject)
424B5 - Nuvation Bio Inc. (0001811063) (Filer)
144 - Nuvation Bio Inc. (0001811063) (Subject)
144 - Nuvation Bio Inc. (0001811063) (Subject)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
Live Leadership Updates
Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage
Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t
Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors. "We are delighted to have Dr. Mashal join our Board of Directors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation's pipeline." "Nuvation Bio is at the forefront of developing therape
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. "We are thrilled to welcome John and Jen to the ProKidney Board. They each have a wealth of experience t
Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer. Dr. Liu will lead Nuvation Bio's clinical development team and collaborate with the executive committee to provide strategic directi
Accomplished biotechnology executive brings over 40 years of commercial and leadership experience across multinational pharmaceutical and biotechnology companies to ShouTi ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the company's board of directors. "It is a true privilege to welcome Dan to ShouTi as Chairman of our board," said Raymond Stevens, Ph.D., Chief Executive Officer, ShouTi. "As an industry veteran with an outstanding track record in guiding companies across all stages of development an
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the second quarter ended June 30, 2021, and provided a business update. "The second quarter of 2021 marked multiple achievements for Nuvation Bio. With the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer, we are advancing our supply chain, product development and manufacturing efforts. For our pipe
NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer, joining the Company's executive management team. In his new role, Dr. Hanley will oversee all early- and late-stage pharmaceutical development and operations, including supply chain, product development and manufacturing efforts, and work closely on commercial planning with Quality, Regulatory Affairs, Clinical Development and Clinical Operations teams.
Live finance-specific insights
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-naïve, highlighting continued momentum in the first-line settingPresented newly updated clinical data demonstrating IBTROZI's impressive durability of response and progression-free survival in TKI-naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) at AACR 2026 Announced acquisition of Japan rights to safusidenib from Daiichi Sankyo, enabling global development and commercialization of promising investigational medicineStrong balance sheet with
NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (
Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and JapanPublished positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant gliomaStrong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025Company to host a conference call today at 4:30 pm ETNEW YORK, March 2, 2026 /PRNewswire/ -- Nuva
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +
Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) increased to 50 months as of August 2025 Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study of IBTROZI for the adjuvant treatment of ROS1+ early-stage NSCLC Strong balance sheet with cash, cash equivalents, and marketable securities of $549.0 million as of Septembe
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 405112. An archived recording will be available on Nuvation Bio's website for 90 days following the event. A
Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval National Comprehensive Cancer Network® added taletrectinib (IBTROZI) as a Preferred Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $607.7 million as of June 30, 2025 Company to host a conference call today at 8:00 a.m. ET Nuvation Bio Inc. (
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 926066. An archived recording will be available on Nuvation Bio's website for 90 days following the event.
Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (
New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some
This live feed shows all institutional transactions in real time.
SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13G - Nuvation Bio Inc. (0001811063) (Subject)
SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13G - Nuvation Bio Inc. (0001811063) (Subject)
SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)